Small molecule inhibitors of kdm5 histone demethylases increase the radiosensitivity of breast cancer cells overexpressing JARID1B

KDM5 enzymes are H3K4 specific histone demethylases involved in transcriptional regulation and \r\nDNA repair. These proteins are overexpressed in different kinds of cancer, including breast, prostate and \r\nbladder carcinomas, with positive effects on cancer proliferation and chemoresistance. For these \r\nreasons, these enzymes are potential therapeutic targets. \r\nIn the present study, we analyzed the effects of three different inhibitors of KDM5 enzymes in MCF-7 \r\nbreast cancer cells over-expressing one of them, namely KDM5B/JARID1B.\r\nIn particular, compounds RS3195, RS3152, RS3183, R^5033 and RS4995 were assayed in terms of H3K4 demethylation (western blot), radio-sensitivity (cytoxicity and clonogenic assays) and damage accumulation (COMET assay and kinetics of H2AX phosphorylation) (Figure 1). We showed that three compounds can selectively inhibit \r\nKDM5 enzymes and are capable of increasing sensitivity of breast cancer cells to ionizing radiation and \r\nradiation-induced damage. These findings confirmed the involvement of H3K4 specific demethylases in \r\nthe response to DNA damage, showed a requirement of the catalytic function and suggested new \r\nstrategies for the therapeutic use of their inhibitors.